Long noncoding RNAs in head and neck cancer

Xiuhua Li, Yongbing Cao, Xiaojian Gong and Hongjiao Li _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:10726-10740. https://doi.org/10.18632/oncotarget.12960

Metrics: PDF 3875 views  |   HTML 3754 views  |   ?  


Xiuhua Li1,2, Yongbing Cao1, Xiaojian Gong1 and Hongjiao Li2

1 School of Pharmacology, China Pharmaceutical University, Nanjing, Jiangsu, P. R. China

2 Department of Stomatology,ChanghaiHospital, Second Military Medical University, Shanghai, P. R. China

Correspondence to:

Hongjiao Li, email:

Xiaojian Gong, email:

Keywords: HNC; lncRNAs; function; mechanism; clinical application

Received: October 05, 2016 Accepted: October 19, 2016 Published: October 27, 2016


Head and neck cancers (HNCs) include a series of malignant tumors arising in epithelial tissues, typically oral cancer, laryngeal cancer, nasopharynx cancer and thyroid cancer. HNCs are important contributors to cancer incidence and mortality, leading to approximately 225,100 new patients and 77,500 deaths in China every year. Determination of the mechanisms of HNC carcinogenesis and progression is an urgent priority in HNC treatment. Long noncoding RNAs (lncRNAs) are noncoding RNAs longer than 200 bps. lncRNAs have been reported to participate in a broad scope of biological processes, and lncRNA dysregulation leads to diverse human diseases, including cancer. In this review, we focus on lncRNAs that are dysregulated in HNCs, summarize the latest findings regarding the function and molecular mechanisms of lncRNAs in HNC carcinogenesis and progression, and discuss the clinical application of lncRNAs in HNC diagnosis, prognosis and therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12960